{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:54:17Z","timestamp":1791190457403,"version":"4.1.0"},"reference-count":29,"publisher":"The Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cinacalcet is predominantly used to treat secondary hyperparathyroidism due to end-stage renal failure, but, more recently, its potential clinical efficacy in treating patients with loss-of-function mutations in the calcium-sensing receptor (CaSR) has been recognized. Many clinically relevant CaSR mutations are located in the heptahelical membrane spanning and extracellular loop regions of the receptor, where allosteric modulators are predicted to bind. The aim of the present study was to investigate the impact of such mutations on the pharmacoregulation of the CaSR by the positive and negative allosteric modulators, cinacalcet and NPS-2143, respectively. Both cinacalcet and NPS-2143 effectively rescued mutants whose cell surface expression was substantially impaired, suggesting that both classes of drug can stabilize a receptor conformation that is trafficked more effectively to the cell surface. In addition, functional impairments in almost all mutant CaSRs were rescued by either cinacalcet or NPS-2143 via restoration of intracellular signaling. There was a significantly greater ability of both compounds to modulate agonist-stimulated intracellular Ca2+ mobilization than ERK1\/2 phosphorylation, indicating that the allosteric modulators engender bias in agonist-stimulated CaSR signaling to different pathways. Three mutations (G670R, P748R, and L773R) altered the binding affinity of allosteric modulators to the CaSR, and 3 mutations (V817I, L773R, and E767K) altered the cooperativity between the allosteric modulator and Ca2+o. These findings have important implications for the treatment of diseases associated with CaSR mutations using allosteric CaSR modulators and for analyzing the effects of mutations on the function and pharmacoregulation of the CaSR.<\/jats:p>","DOI":"10.1210\/en.2012-1887","type":"journal-article","created":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T13:52:41Z","timestamp":1359726761000},"page":"1105-1116","source":"Crossref","is-referenced-by-count":81,"title":["Impact of Clinically Relevant Mutations on the Pharmacoregulation and Signaling Bias of the Calcium-Sensing Receptor by Positive and Negative Allosteric Modulators"],"prefix":"10.1210","volume":"154","author":[{"given":"Katie","family":"Leach","sequence":"first","affiliation":[{"name":"Monash Institute of Pharmaceutical Sciences (K.L., A.W., A.E.C., P.M.S., A.C.), Parkville, 3052, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriel","family":"Wen","sequence":"first","affiliation":[{"name":"Monash Institute of Pharmaceutical Sciences (K.L., A.W., A.E.C., P.M.S., A.C.), Parkville, 3052, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Cook","sequence":"first","affiliation":[{"name":"Monash Institute of Pharmaceutical Sciences (K.L., A.W., A.E.C., P.M.S., A.C.), Parkville, 3052, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Sexton","sequence":"first","affiliation":[{"name":"Monash Institute of Pharmaceutical Sciences (K.L., A.W., A.E.C., P.M.S., A.C.), Parkville, 3052, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur D.","family":"Conigrave","sequence":"first","affiliation":[{"name":"School of Molecular Bioscience (A.D.C.), University of Sydney, Sydney 2006, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Christopoulos","sequence":"first","affiliation":[{"name":"Monash Institute of Pharmaceutical Sciences (K.L., A.W., A.E.C., P.M.S., A.C.), Parkville, 3052, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071612370491800_B1","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"2020071612370491800_B2","doi-asserted-by":"crossref","first-page":"E707","DOI":"10.1210\/jc.2010-1306","article-title":"Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CaSR) R185Q mutation: clinical benefit from cinacalcet","volume":"96","author":"Reh","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612370491800_B3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2796.2006.01684.x","article-title":"Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor","volume":"260","author":"Timmers","year":"2006","journal-title":"J Intern Med"},{"key":"2020071612370491800_B4","doi-asserted-by":"crossref","first-page":"e812","DOI":"10.1542\/peds.2011-0128","article-title":"Successful use of bisphosphonate and calcimimetic in neonatal severe primary hyperparathyroidism","volume":"129","author":"Wilhelm-Bals","year":"2012","journal-title":"Pediatrics"},{"key":"2020071612370491800_B5","doi-asserted-by":"crossref","first-page":"19854","DOI":"10.1074\/jbc.M110.124792","article-title":"Calcium-sensing receptor biosynthesis includes a cotranslational conformational checkpoint and endoplasmic reticulum retention","volume":"285","author":"Cavanaugh","year":"2010","journal-title":"J Biol Chem"},{"key":"2020071612370491800_B6","doi-asserted-by":"crossref","first-page":"9517","DOI":"10.1074\/jbc.M609045200","article-title":"Rescue of calcium-sensing receptor mutants by allosteric modulators reveals a conformational checkpoint in receptor biogenesis","volume":"282","author":"Huang","year":"2007","journal-title":"J Biol Chem"},{"key":"2020071612370491800_B7","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1210\/me.2009-0041","article-title":"Pharmacochaperone-mediated rescue of calcium-sensing receptor loss-of-function mutants","volume":"23","author":"White","year":"2009","journal-title":"Mol Endocrinol"},{"key":"2020071612370491800_B8","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1124\/jpet.109.159228","article-title":"Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine] on correcting inactivating mutations in the human calcium-sensing receptor","volume":"331","author":"Lu","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"2020071612370491800_B9","doi-asserted-by":"crossref","first-page":"18908","DOI":"10.1074\/jbc.M202113200","article-title":"Evidence for distinct cation and calcimimetic compound (NPS 568) recognition domains in the transmembrane regions of the human Ca2+ receptor","volume":"277","author":"Ray","year":"2002","journal-title":"J Biol Chem"},{"key":"2020071612370491800_B10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/prot.21685","article-title":"Improved model building and assessment of the calcium-sensing receptor transmembrane domain","volume":"71","author":"Bu","year":"2008","journal-title":"Proteins"},{"key":"2020071612370491800_B11","doi-asserted-by":"crossref","first-page":"21558","DOI":"10.1074\/jbc.M603682200","article-title":"A missense mutation in the seven-transmembrane domain of the human Ca2+ receptor converts a negative allosteric modulator into a positive allosteric modulator","volume":"281","author":"Hu","year":"2006","journal-title":"J Biol Chem"},{"key":"2020071612370491800_B12","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1074\/jbc.M307191200","article-title":"Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site","volume":"279","author":"Miedlich","year":"2004","journal-title":"J Biol Chem"},{"key":"2020071612370491800_B13","doi-asserted-by":"crossref","first-page":"18990","DOI":"10.1074\/jbc.M400724200","article-title":"Positive and negative allosteric modulators of the Ca2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain","volume":"279","author":"Petrel","year":"2004","journal-title":"J Biol Chem"},{"key":"2020071612370491800_B14","doi-asserted-by":"crossref","first-page":"49487","DOI":"10.1074\/jbc.M308010200","article-title":"Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca2+-sensing receptor","volume":"278","author":"Petrel","year":"2003","journal-title":"J Biol Chem"},{"key":"2020071612370491800_B15","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1210\/en.2012-1449","article-title":"Identification of molecular phenotypes and biased signaling induced by naturally occurring mutations of the human calcium sensing receptor","volume":"153","author":"Leach","year":"2012","journal-title":"Endocrinology"},{"key":"2020071612370491800_B16","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1124\/mol.108.049353","article-title":"New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug)","volume":"74","author":"Nawaratne","year":"2008","journal-title":"Mol Pharmacol"},{"key":"2020071612370491800_B17","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1210\/en.2011-1426","article-title":"Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor","volume":"153","author":"Davey","year":"2012","journal-title":"Endocrinology"},{"key":"2020071612370491800_B18","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1210\/me.2004-0080","article-title":"Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059","volume":"18","author":"Bernier","year":"2004","journal-title":"Mol Endocrinol"},{"key":"2020071612370491800_B19","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1172\/JCI8688","article-title":"Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants","volume":"105","author":"Morello","year":"2000","journal-title":"J Clin Invest"},{"key":"2020071612370491800_B20","doi-asserted-by":"crossref","first-page":"47254","DOI":"10.1074\/jbc.M408154200","article-title":"Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors","volume":"279","author":"Wuller","year":"2004","journal-title":"J Biol Chem"},{"key":"2020071612370491800_B21","doi-asserted-by":"crossref","first-page":"F253","DOI":"10.1152\/ajprenal.00247.2006","article-title":"Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus","volume":"292","author":"Robben","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"2020071612370491800_B22","doi-asserted-by":"crossref","first-page":"14442","DOI":"10.1074\/jbc.M300087200","article-title":"Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa","volume":"278","author":"Noorwez","year":"2003","journal-title":"J Biol Chem"},{"key":"2020071612370491800_B23","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1210\/jcem.87.7.8582","article-title":"Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target","volume":"87","author":"Janovick","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612370491800_B24","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/jpet.102.048454","article-title":"Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor","volume":"305","author":"Janovick","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"2020071612370491800_B25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/j.ajkd.2008.09.021","article-title":"A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis","volume":"53","author":"Chonchol","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2020071612370491800_B26","doi-asserted-by":"crossref","first-page":"ra78","DOI":"10.1126\/scisignal.2002208","article-title":"Agonist-driven maturation and plasma membrane insertion of calcium-sensing receptors dynamically control signal amplitude","volume":"4","author":"Grant","year":"2011","journal-title":"Sci Signal"},{"key":"2020071612370491800_B27","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1210\/me.2012-1232","article-title":"Calcium signaling regulates trafficking of familial hypocalciuric hypercalcemia (FHH) mutants of the calcium sensing receptor","volume":"26","author":"Grant","year":"2012","journal-title":"Mol Endocrinol"},{"key":"2020071612370491800_B28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ceca.2011.11.009","article-title":"Biased agonism of the calcium-sensing receptor","volume":"51","author":"Thomsen","year":"2012","journal-title":"Cell Calcium"},{"key":"2020071612370491800_B29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0165-6147(98)01240-1","article-title":"Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log","volume":"19","author":"Christopoulos","year":"1998","journal-title":"Trends Pharmacol Sci"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/154\/3\/1105\/10385970\/endo1105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/154\/3\/1105\/10385970\/endo1105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T20:55:56Z","timestamp":1594932956000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/154\/3\/1105\/2423464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,1]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2012-1887","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,1]]}}}